From science risk to market fit - Cradle’s Stef van Grieken on building a biotech venture in Europe

Most founders wait until Series A to clean up their cap table. Stef did the opposite - and spent $70K upfront just to get the foundations right.

As co-founder of Cradle, he built a biotech company for global scale from day one: navigating European legal complexity, validating science in skeptical labs, and paying early customers out of pocket to prove it worked.

In this episode, we get into:

• ​Why Cradle paid its first two customers—and how that unlocked top-tier pharma clients
• ​How to structure your company early to avoid massive headaches later
• ​Why European startup culture struggles with ambition—and what needs to change
• ​How to hire ML talent in Europe when OpenAI is knocking on the same doors
• ​

🟢 And before you go, subscribe to our free newsletter at ⁠⁠⁠⁠⁠⁠⁠followthegradient.io⁠⁠⁠⁠⁠⁠⁠. Twice a week, we break down startup and tech news, share exclusive insights from our podcast guests, highlight top job openings from European startups, and provide food for thought you won’t find anywhere else. 🟡